Protembis Secures €30M in Series B Funding; Welcomes Keith D Dawkins MD to Board

By , in Germany on . Tagged width: ,

Protembis GmbH, a privately owned emerging cardiovascular medical device enterprise, announced today the successful conclusion of a €30 million Series B financing endeavor.

This financial backing is earmarked to bolster the enrollment of the PROTEMBO Investigational Device Exemption (IDE) Pivotal Trial (NCT05873816). The funding round was crafted through two distinct capital injections, both fulfilled. Noteworthy is the joint leadership in this endeavour by a European consortium of venture capital investors comprising Segulah Medical Acceleration from Sweden, XGEN Venture from Italy, and TechVision Fund from Germany. Additional backers encompass Coparion, numerous substantial family offices, angel investors, and a multinational medical device strategic partner.

Karl von Mangoldt and Conrad Rasmus, Co-CEOs of Protembis, expressed their gratitude to existing and new investors for their resolute trust and confidence. They remarked that the field of cerebral embolic protection is thriving, with future expansion anticipated among younger and lower-risk patients who are unequivocally intolerant of brain injury risk when opting for transcatheter aortic valve replacement.

Karl von Mangoldt and Conrad Rasmus Co-CEOs of Protembis
Karl von Mangoldt and Conrad Rasmus Co-CEOs of Protembis

Furthermore, Protembis is elated to welcome Keith D. Dawkins, MD, to its esteemed Board of Directors. Dr. Dawkins boasts over 35 years of expertise in the cardiovascular domain. Having spent over two decades as a practising interventional cardiologist in the UK, he has undertaken research roles as a Fulbright Scholar at Stanford University. He has also served as President of the British Cardiovascular Intervention Society and has authored over 750 academic publications and presentations.

Dr. Dawkins has held the position of Chief Medical Officer (CMO) at Shockwave (NASDAQ: SWAV) since 2019, following his tenure as Global CMO at Boston Scientific, where he held senior roles since 2008. Additionally, he serves on the boards of Ventric Health LLC and JenaValve Technology Inc., and acts as Chairman of InnovHeart s.r.l. Dr. Dawkins will leverage his profound expertise to steer the clinical strategies of Protembis and pre-commercial programs as the IDE study nears completion.

Azin Parhizgar, PhD, Chairwoman of the Board of Directors, hailed the addition of Dr. Dawkins as a visionary leader, underscoring the transformative potential of cerebral embolic protection for future transcatheter therapies. She anticipated close collaboration as the field evolves and the superiority trial garners momentum.

Dr. Dawkins expressed his enthusiasm about joining Protembis, highlighting his enduring commitment to safeguarding the brain from all new lesions during transcatheter aortic valve replacement. He commended the novelty of the ProtEmbo System and the clinical trial design, expressing confidence in their potential to significantly disrupt the field of cerebral embolic protection and mitigate existing concerns within the physician community.